ReviewJournal of clinical medicine2020
Effective Asthma Management: Is It Time to Let the AIR out of SABA?
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.PloS one · 2023Pooled it
- Airway inflammation and asthma control in patients using salbutamol or budesonide/formoterol reliever: a randomised, controlled study.ERJ open research · 2026Article
- Patient perspectives of asthma treatment and belief barriers to implementing new guidelines: a qualitative analysis of an online forum.NPJ primary care respiratory medicine · 2026Article
- Estimation of carbon emissions from inhaled respiratory medicines in Ireland: a cross-sectional study from a national pharmacy claims database from 2020 to 2022.International journal of clinical pharmacy · 2026Article
- BetaFrontiers in medicine · 2026Review
- Reported use of anti-asthmatic medication in doping control forms from 2015 to 2019 - mapping retrospective data.Frontiers in sports and active living · 2026Article
- Disease Burden of Asthma Patients Utilizing Short-Acting Beta-2 Agonist-Only Inhalers as Rescue in the United States.Journal of asthma and allergy · 2026Article
- Over-reliance on short-acting beta-agonists (SABAs) in asthma: a mixed method study, in primary care, in Greece.NPJ primary care respiratory medicine · 2025Article
- Too Much SAMA, Too Many Exacerbations: A Call for Caution in Asthma.Journal of clinical medicine · 2025Article
- Controversies in Allergy: Should I Combine an ICS With a SABA or With Formoterol for Reliever Therapy?The journal of allergy and clinical immunology. In practice · 2025Review
- Improving asthma outcomes in Kuwait through a standardized emergency department algorithm.The World Allergy Organization journal · 2025Article
- Asthma management in India: Changing paradigms.The Indian journal of medical research · 2025Article
- Evaluating the uptake of a Global Initiative for Asthma guideline update in a commercially insured, value-based care population.Journal of managed care & specialty pharmacy · 2025Observational
- Glucocorticoid Insensitivity in Severe Asthma: Underlying Molecular Mechanisms, Challenges, and Emerging Therapies.Archives of internal medicine research · 2025Article
- Perceptions, practices, and experiences of asthma patients and community pharmacists on short-acting beta-2 agonists inhaler use: A qualitative study.Journal of pharmaceutical policy and practice · 2025Article
- How do patients determine when their inhaler is empty? Insights from an analysis of returned inhalers and a patient survey.BMJ open respiratory research · 2024Article
- Primary healthcare professionals' perceptions, attitudes and ideas regarding asthma management in Greece: A mixed-method study.The European journal of general practice · 2024Article
- The need for implementing a standardized, evidence-based emergency department discharge plan for optimizing adult asthma patient outcomes in the UAE, expert meeting report.International journal of emergency medicine · 2024Review
- Over-the-counter short-acting βNPJ primary care respiratory medicine · 2024Article
- Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations.BMC pulmonary medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes. Instead, the more appropriate course is the use of a combined inhaled corticosteroid-fast acting beta agonist as a reliever. This paper discusses the issues associated with the use of SABA, the reasons that patients over-use SABA, difficulties that can be expected in overcoming SABA over-reliance in patients, and our evolving understanding of the use of "anti-inflammatory relievers" in our patients with asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.